Additive action of gemcitabine (2',2'-difluorodeoxycytidine) and 2- chlorodeoxyadenosine on murine leukemias L1210 and P388

Cancer Investigation

Volumn 17, Issue 2, 1999, Pages 95-101

  Marañda, Ewa ^a   Szmigielska, Anna ^a   Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

2 Chlorodeoxyadenosine; Gemcitabine; Interactions; Leukemias; Murine

Indexed keywords

CLADRIBINE; GEMCITABINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG EFFICACY; HUMAN CELL; HUMAN TISSUE; LEUKEMIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; SURVIVAL TIME;

EID: 0345003842     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1080/07357909909011722     Document Type: Article

References (25)

1. Lund B, Kristjansen PEG, Hansen H: Clinical and preclinical activity of 2′2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 19:45-55, 1993.
2. Plunkett W, Huang P, Searcy CE, et al: Gemcitabine: preclinical pharmacology and mechanism of action. Semin Oncol 23(Suppl 10):3-15, 1996.
3. Plunkett W, Huang P, Xu YZ, et al: Gemcitabine: metabolism, mechanism of action, and self-potentiation. Semin Oncol 22(Suppl 11):3-10, 1995.
4. Plunkett W, Huang P, Gandhi V: Preclinical characteristics of gemcitabine. Anticancer Drugs 6(Suppl 6):7-13, 1995.
5. Heinemann V, Hertel LW, Grindey GB, et al: Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res. 48:4024-4031, 1988.
6. Beutler E: Cladribine (2-chlorodeoxyadenosine). Lancet 340: 952-956, 1992.
7. Lauria F: 2-Chlorodeoxyadenosine, a "novel" agent in the treatment of both lymphoid and myeloid malignancies. Haematologica 77:443-445, 1992.
8. Carson DA, Wasson DB, Beutler E: Antileukemic and immuno-suppressive activity of 2-chloro-2′-deoxyadenosine. Proc Natl Acad Sci USA 81:2232-2236, 1984.
9. Piro LD: 2-Chlorodeoxyadenosine: drug development priorities. J Clin Oncol 10:1507-1509, 1992.
10. Santana VM, Hurvitz CA, Blakley RL, et al: Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 84:1237-1242, 1984.
11. Saven A, Lemon R, Fignerou M, et al: Complete hematologic remission in stable, Ph-chromosome positive, chronic myeloid leukemia (CML) following 2-chlorodeoxyadenosine (2-CdA). Proc Am Soc Clin Oncol 310:10-22, 1993.
12. Robak T, Korycka A: The comparison of 2-chlorodeoxyadenosine (2-CdA) in combination with interferon γ (IFNγ) on granulocyte-macrophage progenitor cells (CFU-GM) and clonogenic blasts (CFU-L) in in-vitro cultures. Leuk Lymph 21:161-168, 1996.
13. Góra-Tybor J, Robak T, Warzocha K, et al: Influence of 2-chloro2-deoxyadenosine alone and in combination with cyclophosphamide and methotrexate on murine leukemias L1210. Arch Immunol Ther Exp 42: 39-42, 1994.
14. Góra-Tybor J, Robak T: Synergistic action of 2-chlorodeoxyadenosine with cyclophosphamide on murine leukemias L1210 and P388. Acta Haematol Pol 24:174-182, 1993.
15. Szmigielska A. Góra-Tybor J, Robak T: Influence of 2-chlorodeoxyadenosine alone and in combination with cytosine arabinoside on murine leukemias L1210 and P388. Cancer J 9:319-322, 1996.
16. Gandhi V, Estey E, Keating MJ, et al: Chlorodeoxyadenosine and arabinosyl cytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic and molecular interactions. Blood 87:256-264, 1996.
17. Hertel LW, Boder GB, Kroin JS, et al: Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50:4417-4422, 1990.
18. Kazimierczuk Z, Vilpo J, Hildebrand C, et al: Synthesis and cytotoxicity of deoxyadenosine analogues: isomer distribution in the sodium salt glycosylation of 2,6-disubstituted purines. J Med Chem 33:1683-1687, 1990.
19. Geran RJ, Greenberg NH, MacDonald MM, et al: Protocols for screening chemical agents and natural products against animal tumor and other biological systems. Cancer Chemother Rep 3:1, 1972.
20. Hanauske AR, Degen D, Marshall MH, et al: Activity of 2′,2′-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units. Anti-Cancer Drugs 3:143-147, 1992.
21. Bouffard DY, Momparler LF, Momparler RL: Comparison of the antineoplastic activity of 2′,2′-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells. Anti-Cancer Drugs 2:49-56, 1991.
22. Huang P, Chubb S, Hertel LW, et al: Action of 2′2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110-6117, 1991.
23. Peters GJ, Ruiz van Haperen VWT, Bergman AM, et al: Preclinical combination therapy with gemcitabine and mechanism of resistance. Semin Oncol 23(Suppl 10):16-24, 1996.
24. Bouffard DY, Momparler RL: Comparison of the induction of apoptosis in human leukemic cell lines by 2′,2′-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. Leuk Res 11:849-856, 1995.
25. Gandhi V, Estey E, Keating MJ, et al: Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11:116-124, 1993.